Top 50 Life Science VC (Venture Capital) Funds in United States in May 2025
A list of 50 VC (Venture Capital) funds that invest in Life science startups based in United states. We rank investors based on the number of investments they made in Life science companies from United states. We update this investor list every month.Top 50 Life Science VC (Venture Capital) Funds in United States in May 2025
Investor | Life Science United States investments |
---|---|
ARCH Venture Partners | 24 |
SOSV | 21 |
Alexandria Venture Investments | 20 |
Northpond Ventures | 19 |
RA Capital Management | 15 |
Novartis Venture Fund | 14 |
Atlas Venture | 13 |
Third Rock Ventures | 13 |
8VC | 12 |
DCVC | 12 |
Alix Ventures | 12 |
Andreessen Horowitz | 11 |
Hatteras Venture Partners | 11 |
Civilization Ventures | 11 |
Fifty Years | 11 |
OrbiMed | 10 |
KdT Ventures | 10 |
MPM Capital | 10 |
Sahsen Ventures | 10 |
Google Ventures | 9 |
Artis Ventures | 9 |
Versant Ventures | 9 |
Rev1 Ventures | 9 |
Longwood Fund | 9 |
Apple Tree Partners | 8 |
The Column Group | 8 |
5AM Ventures | 8 |
SR One | 8 |
Lux Capital | 8 |
Playground Global | 8 |
Vivo Capital | 8 |
Pear VC | 8 |
Cormorant Asset Management | 8 |
iSelect Fund | 8 |
New Enterprise Associates | 8 |
Illumina Ventures | 7 |
Roche Venture Fund | 7 |
Foresite Capital | 7 |
Horizons Ventures | 7 |
Omega Funds | 7 |
Flagship Pioneering | 7 |
Digitalis Ventures | 7 |
Mission BioCapital | 7 |
Breakout Ventures | 7 |
Dolby Family Ventures | 7 |
Connecticut Innovations | 7 |
Two Sigma Ventures | 6 |
Canaan Partners | 6 |
Boxer Capital | 6 |
Takeda Ventures | 6 |
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, United Kingdom
Portfolio highlights
- Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
- Kardigan — Kardigan is building the heart health company of the future focused on developing medicines to make cardiovascular disease curable, preventable, and no longer the leading cause of death.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Canada, France
Portfolio highlights
- Remedy Plan Therapeutics — Remedy Plan is a biotechnology company developing the first drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis.
- Hoofprint Biome — Hoofprint Biome, developing probiotics for to increase feed digestibility and decreasing methane in cattle
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
- VieCure — The VieCure platform is an Clinical Decision Support solution in Oncology that combines the power of artificial intelligence, codified clinical rules and pathways, precision oncology, telehealth, smartphone technology, and the EMR to transform cancer care.
- Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Post-IPO Equity
- United States, United Kingdom, Canada
Portfolio highlights
- Stylus Medicine — Stylus Medicine, Inc. is a biotechnology company dedicated to developing transformative in vivo genetic medicines.
- Jade Biosciences — Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.
- Imbria Pharmaceuticals — Imbria is a clinical-stage, cardio-metabolic company developing innovative cellular energy enhancing therapies for the treatment of cardiovascular disorders
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
- Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
- Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
- Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
- Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Gallatin — Gallatin is building a logistics platform based on the needs and constraints of today's defense industry. Gallatin's platform creates actionable insights across the tactical, operational, and strategic levels providing integrated capabilities for first, middle, and last mile solutions where they're needed most.
- Apex — Apex manufactures ESPA-class satellites, ranging from 40 to 400kg. Our first spacecraft bus platform, Aries, is built for LEO missions for earth observation, communications, and more. Configure the Aries bus to meet your specific mission profile.
- Chaos — The future of defense and critical industry technology. Creating that which has never been.
We are deep tech venture capital.
Show more
Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Lumafield — Lumafield's easy-to-use CT scanner and cloud-based software give engineers the ability to see their work clearly, inside and out.
- Fervo Energy — Fervo Energy delivers 24/7 carbon-free energy through development of next-generation geothermal projects.
- Alta Resource Technologies — Alta Resource Technologies is on a mission to reinvent mining by harnessing advanced biochemistry to cost-effectively source the critical raw materials needed to power next-generation technology and bolster economic security. Our groundbreaking technology platform leverages customizable proteins to separate high-purity rare earth elements and otheressential minerals with unprecedented selectivity while dramatically reducing the environmental impact of mining.
Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....
Show more
Investment focus
- Health Care, Biotechnology, Life Science
- Series A, Seed, Pre-Seed
- United States
Portfolio highlights
- Elegen — Skip cloning with NGS-verified, cell-free DNA up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, shipped globally in 6 to 8 business days. .
- Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
- Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
- Software, Information Technology, Internet
- Series A, Seed, Series B
- United States, United Kingdom, Brazil
Portfolio highlights
- Hedra — Video creation for everyone.
- Inductive Bio — Bringing the data, ML, software, and expertise needed to rapidly solve your most challenging ADMET problems.
- Sprinter Health — Sprinter Health is an on-demand mobile health company that sends full-time nurses and phlebotomists (“Sprinters”) into the home.
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Funding Round
- United States, Canada
Portfolio highlights
- Endogenex — DyaMX is an early stage medical device company focused on the treatment of Type 2 Diabetes
- Synaptrix — Synaptrix is committed to offering free of drugs, lasting alternatives for postoperative pain treatment using NOVABLOC.
- AtaCor Medical — AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.
DIGITAL HEALTH / AI
DIGITAL HEALTH / AI GENE / CELL THERAPIES
NASDAQ: RCKT GENE / CELL THERAPIES
NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS
SYNTHETIC
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, United Kingdom, Brazil
Portfolio highlights
- SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
- Integrated Biosciences — Integrated Biosciences is the first company in history to be able to virtually stress cells.
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Germany, Canada
Portfolio highlights
- Deepcell — Deepcell uses AI to isolate and capture cells based on morphological features for multiple research and translational applications.
- Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
- Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, China, Israel
Portfolio highlights
- RayThera — RayThera specializes in developing breakthrough small molecule therapies for critical unmet needs in immunology. Backed by decades of drug discovery expertise, we accelerate the development process while maintaining rigorous standards.
- Stairway Medical — Stairway Medical is a developer of implantable brain-computer interface technology.
- Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Israel, Germany
Portfolio highlights
- Shiprocket — Shiprocket is India's most-used eCommerce logistics and shipping software solution for the best courier services. Avail features like COD (Cash on Delivery), prepaid delivery, automated shipping, etc.
- March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
Powering Breakthroughs in Life Sciences
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
- Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
- Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.
Show more
Investment focus
- Biotechnology, Health Care, Non Profit
- Funding Round, Series A, Seed
- United States, China, Ghana
Portfolio highlights
- Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
- Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.
GV supports innovative founders moving the world forward.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Series B, Seed
- United States, United Kingdom, Switzerland
Portfolio highlights
- Veza — Veza is the identity security company that enables organizations to understand, manage and control who can and should take what action on what data.
- Blacksmith — Blacksmith is a company that helps businesses to conduct their continuous integration (CI) up to twice as quickly and at half the expense. Blacksmith accomplish this by running CI on powerful gaming CPUs.
- Glass Imaging — Traditional cameras rely on an imaging lens which typically consists of several lens elements and a light sensitive sensor. Cameras have been built like this since 1816. Glass has been historically used to make high quality optical elements. We are replacing these elements with deep neural networks that give extreme flexibility when designing ourcameras. It allows us to squeeze a huge sensor into an ultra thin module that fits perfectly into a mobile device without the need for protruding bumps. Our cameras bring SLR image quality into your pocket.
Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Series A, Series B, Seed
- United States, India, Germany
Portfolio highlights
- Network Bio — Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
- Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Switzerland, Canada
Portfolio highlights
- Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
- Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
- Light Horse Therapeutics — Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.
Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!
Show more
Investment focus
- Software, Health Care, Information Technology
- Seed, Series A, Funding Round
- United States, Germany
Portfolio highlights
- Myoptechs — Myoptechs, a pediatric ophthalmic medical device startup in the clinical stage, has made advancements in its fund-raising and clinical research program. The company creates innovative soft contact lenses and spectacles that reduce the growth of myopia while offering incredibly clear vision.
- Nichefire — Nichefire is an AI-power marketing analytics company.
- STAQ Pharma — STAQ Pharma is an FDA-registered 503B outsourcing partner that provides critical medications for pediatric and adult patients across the country. As a hospital-backed and directed pharmaceutical outsourcing partner, STAQ Pharma is positioned to strengthen the supply chain for drug shortages, understand provider needs, and ensure safety in critical medications.
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems
Show more
Investment focus
- Biotechnology, Therapeutics, Health Care
- Series A, Series B, Series C
- United States, United Kingdom, Italy
Portfolio highlights
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Newleos Therapeutics — Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Canada, United Kingdom
Portfolio highlights
- Ascidian Therapeutics — Ascidian Therapeutics is a biotechnology company developing exon-editing RNA therapeutics to target the underlying causes of disease.
- Red Queen Therapeutics — Staying ahead of viral threats with new innovations in antiviral therapy
- Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- Rapt Therapeutics — RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.
- Eikon Therapeutics — Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life.
- Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries.
5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Surrozen — Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
- nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
- Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
- Kala Pharmaceuticals — Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Seed, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- Saildrone — Saildrone is the world leader in oceangoing autonomous surface vehicles, providing unrivaled payload, range, and reliability from an uncrewed system.
- Inductive Bio — Bringing the data, ML, software, and expertise needed to rapidly solve your most challenging ADMET problems.
- Jericho Security — Train your team to defend against the latest cyber attacks with our complete cybersecurity platform.
Playground is an early-stage investment firm that helps old and new investors and entrepreneurs working at the intersection of bits, atoms, and AI. It focuses on investment, innovation, connected hardware, artificial intelligence, and robotics.
Show more
Investment focus
- Software, Robotics, Artificial Intelligence
- Series A, Seed, Series B
- United States, Canada, France
Portfolio highlights
- Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
- GigaCrop — Perlumi is engineering seeds to turbocharge photosynthesis for unprecedented bounty.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts.
The firm operates as a multi-fund investment platform, covering growth equity, private
equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series C, Post-IPO Equity
- United States, China, United Kingdom
Portfolio highlights
- 35Pharma — 35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.
- Trevi Therapeutics — Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
- Chentai New Materials — Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products.
Pear VC partners with entrepreneurs from day zero to build category-defining companies.
Show more
Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Series A, Pre-Seed
- United States, Brazil, Colombia
Portfolio highlights
- Phaselaw — Phaselaw is an AI-enhanced eDiscovery platform that significantly speeds up and simplifies the review and redaction of large document collections, tailored especially for legal, HR, and compliance teams managing disclosures, litigation, or regulatory inquiries.
- Nuvo — Onboard customers through configurable, high-converting branded experiences that accelerate credit approvals, unlock revenue, and reduce fraud.Nuvo replaces manual credit forms with AI-powered application flows, real-time business and principal identity verification, and embedded credit insights—enabling confident decisions that protect and growyour business. Designed for complex trade partnerships, Nuvo is the B2B commerce platform trusted and preferred by 40,000 businesses.
- Glide — Glide redefines account opening and lending with seamless digital experiences. Simplify account opening and loan origination with a platform built to drive growth, enhance experiences, and streamline operations.
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, China, Switzerland
Portfolio highlights
- Numab — Numab Therapeutics AG
- Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
- Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.
Venture investing in Food, Health, and AgTech. A generational investment thesis. Food is Health is longevity
Show more
Investment focus
- Biotechnology, Health Care, Agriculture
- Seed, Series A, Series B
- United States, Australia
Portfolio highlights
- Edacious — Edacious is a new food system. Our company can help you differentiate the quality of your food.
- one.bio — BCD Bioscience is an emerging biotechnology spinout from UC Davis that creates ingredients for food and biopharmaceutical applications. The company was founded in 2019 and is headquartered in Davis, California, United States.
- Growers Edge — Growers Edge leverages data science to build grower-relevant risk management solutions to meet ever-changing agricultural demands.
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Series B, Series C
- United States, India, Canada
Portfolio highlights
- Arkestro — Bid Ops is the only predictive procurement software built to keep your team continuously exceeding targets. Using Bid Ops, you can orchestrate your activities across systems using instant forecasts and real-time collaboration. Predict and win 2-5x faster savings and never get stuck waiting for a KPI report again. Learn more athttps://www.bidops.com
- Wonder — Introducing a new kind of home dining experience. Currently available in areas of New Jersey.
- Samaya AI — The company specializes in developing AI research agents that streamline knowledge workflows.
We invest in companies that are advancing the field of genomics and pioneering new applications in healthcare, agriculture, environmental science, and personal
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Series C
- United States, United Kingdom, France
Portfolio highlights
- SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
- Attovia Therapeutics — Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated.
- Predicta Biosciences — Our blood-based approach unlocks true precision medicine.
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, United Kingdom, Spain
Portfolio highlights
- DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
- Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, Australia
Portfolio highlights
- RayThera — RayThera specializes in developing breakthrough small molecule therapies for critical unmet needs in immunology. Backed by decades of drug discovery expertise, we accelerate the development process while maintaining rigorous standards.
- Eikon Therapeutics — Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life.
- Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more
Investment focus
- Biotechnology, Artificial Intelligence, Software
- Series A, Series B, Seed
- United States, United Kingdom, Canada
Portfolio highlights
- Notpla — We are a combination of designers and chemists, engineers and entrepreneurs. We’re hard to define because what we’re doing hasn’t been done before. We create advanced packaging solutions that disappear, naturally.
- Owlstone Medical — Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease, and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novelnon-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA Breath Sampler ensures a reliable collection of breath samples. The volatile organic compounds (VOCs) present in the breath are analyzed using proven microchip chemical sensor technology (FAIMS) to detect biomarkers of disease.The Breath Biopsy platform can be used in clinical diagnostics and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by the therapeutic response. The company also Breath Biopsy products and services to academic, clinical, and pharma partners who want to develop breath-based diagnostics for their own applications.
- Fleet Space Technologies — Fleet is an agile, next generation connectivity company. Our mission is to Connect Everything using cutting-edge communications and space technologies to maximise the resource efficiency of human civilisation and enable the next industrial revolution with our free, ubiquitous connectivity platform.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
- Alleviant Medical — Interventional therapy for congestive heart failure
- Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series C, Series A
- United States, Canada, United Kingdom
Portfolio highlights
- Mirai Bio — Mirai Bio has developed an open platform powered by AI to address the main drawbacks and manufacturing to develop the future of genetic medicine.
- Inari — Inari is a biotech seed company that embraces diversity in every aspect of its business to drive innovation and help build a new food system. Our technology matches the complexity of nature using predictive design and multiplex gene editing to unlock the full potential of seed. We are always innovating, pushing the boundaries of what’s possible.Our SEEDesign platform is our point of distinction, using unsurpassed technology to enhance any crop for any geography to develop step-change products with a clear go-to-market approach.
- Prologue Medicines — Prologue is systematically discovering the therapeutic potential of secreted proteins tuned through millennia of natural evolution to rapidly create powerful new medicines.
Engineering solutions to complex problems in health through venture investment and company creation.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Seed
- United States, United Kingdom, China
Portfolio highlights
- Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
- Nuvig Therapeutics — Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmunediseases.
- Aviceda Therapeutics — Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination ofcutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation.Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively.
Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they areknown by leaders of portfolio companies for the expertise and deep support they provide.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Funding Round, Series B
- United States, Germany, Switzerland
Portfolio highlights
- D2B3 — The future of treating brain diseases.
- Alessa Therapeutics — We drive innovation in oncology and solid organ disease through development of advanced treatment and early interception.
- SiteOne Therapeutics — SiteOne develops selective inhibitors of sodium channels as non-opioid treatments to address acute and chronic pain
Breakout Ventures is a new, early stage fund that backs bold scientist entrepreneurs working at the intersections of technology, biology, materials, and energy.
Show more
Investment focus
- Biotechnology, Life Science, Therapeutics
- Seed, Series B, Series A
- United States
Portfolio highlights
- CytoVale — Cyotvale offers IntelliSep, an FDA-cleared early sepsis detection test powered by the Cytovale System medical device.
- Passkey — Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs). It is designed to address complex diseases by targeting rare combinations of proteins that work together.
- Copernic Catalysts — Mantel is developing the material solution to carbon capture
Investing in early-stage companies solving the biggest science and engineering challenges since 2014.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Seed, Series B
- United States, Austria, Switzerland
Portfolio highlights
- NeuroBionics — NeuroBionics aims to advance neurotech and human health through bioelectronic medicine, by developing devices that seamlessly integrate with the human body.
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
- Esper Satellite Imagery — Esper is building and launching the world's most versatile satellite imagery network for mineral exploration, agronomy, and national security. Task imagery now.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Funding Round
- United States, Israel, Canada
Portfolio highlights
- Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
- VeraDermics — VeraDermics Inc. is a dermatology pharmaceutical start-up, makers of WartPatch
- PHȲND — PHȲND is a subscription-free cloud gaming platform that offers a way to discover, play, and socialize across a wide variety of games.
We are an early-stage venture capital firm investing in transformative companies harnessing information growth and computing power to change the world.
Show more
Investment focus
- Software, Machine Learning, Artificial Intelligence
- Series A, Seed, Series B
- United States, Canada, Mexico
Portfolio highlights
- Gameto — Gameto is a new breed of biotechnology company in female reproductive longevity
- Etched.ai — Transformers etched into silicon. By burning the transformer architecture into our chips, we're creating the world's most powerful servers for transformer inference.
- Xaira Therapeutics — Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more
Investment focus
- Software, Biotechnology, Health Care
- Series A, Series B, Series C
- United States, United Kingdom, Israel
Portfolio highlights
- WiseLayer — WiseLayer's AI empowers finance teams to improve profitability & efficiency in minutes per week
- Page — Page, an AI-powered external relations platform that provides real-time insights to help enterprises navigate government policies, media, and regulations.
- Wise Layer — WiseLayer makes AI-powered digital workers for finance and accounting teams.It's AI digital workforce includes: - Angela, the AI agent for Accruals & Rev Rec (hire her at www.accruals.ai) - Dennis, the AI agent for Discrepancies & Financial Anomalies (hire him at www.discrepancies.ai) - … with the 4 newest AI agents eachspecializingin the following tasks: (1) bank reconciliations, (2) fixed asset depreciation & amortization, (3) lease accounting, and (4) prepaid expenses.
Boxer Capital caters to public companies based in the biotechnology industry.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Post-IPO Equity, Series C
- United States, Canada, United Kingdom
Portfolio highlights
- Ajax Therapeutics — Ajax Therapeutics is an NYC-based biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies
- Crescent Biopharma — Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors.
- Century Therapeutics — Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapies.
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Funding Round
- United States, United Kingdom, Israel
Portfolio highlights
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.
- EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.
Investors by industry
Impact
Biotech
Gaming
FinTech
Google
Energy
Proptech
Marketplace
Consumer
Hardware
Artificial intelligence
Health Care
Climate
Community
EdTech
Sustainability
Venture Capital
Clean Energy
Real Estate
Financial Services
Video Games
B2B
Education
Publishing
Finance
Food and Beverage
Beauty
Infrastructure
Web3
Photography
Retail
Big Data
Organic Food
Social Media
Medical
Internet
Manufacturing
eSports
Payments
Construction
Digital Media
Art
Local
Mobile Advertising
Sports
Music
Enterprise Software
Social Network
Wellness
Email
Franchise
Android
Mobile
Legal
Platforms
Automotive
Medical Device
Social
Crowdfunding
Wine And Spirits
CleanTech
Transportation
Mobile Apps
InsurTech
Cannabis
Hospitality
Biotechnology
Travel
Fitness
Recruiting
Enterprise
LGBT
Fashion
Oil and Gas
Film
Life Science
Theatre
Non Profit
Renewable Energy
SaaS
Sporting Goods
Celebrity
Restaurants
Social Impact
Software
Machine Learning
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
United Kingdom
Germany
India
United States
Ireland
South Korea
Canada
Australia
New Zealand
Middle East
Oceania
Europe
Asia
South Africa
Armenia
Brazil
Qatar
Indonesia
Spain
China
Saudi Arabia
Sri Lanka
Vietnam
Africa
LATAM
Japan
Singapore
Finland
Estonia
Hungary
Ethiopia
Hong Kong
Georgia
Egypt
Ecuador
Denmark
France
Faroe Islands
Ghana
Croatia
Gibraltar
Bulgaria
Chile
Belize
Barbados
Costa Rica
Greece
Belgium
Bahrain
Belarus
Bermuda
Czech Republic
Algeria
Mali
Mexico
Liberia
Israel
Philippines
Malaysia
Italy
Lithuania
Liechtenstein
Kuwait
Norway
Morocco
Myanmar
Lebanon
Mauritius
Peru
Jersey
Panama
Malta
Nicaragua
Sweden
El Salvador
Uruguay
Portugal
Zambia
Ukraine
Uzbekistan
Senegal
Seychelles
Venezuela
Tajikistan
Taiwan
Serbia
Uganda
Sierra Leone
Turkey
Thailand
Tunisia
San Marino
Rwanda
Puerto Rico
Poland
Russian Federation
Tanzania
Slovenia
Zimbabwe
Togo
Dominican Republic
Azerbaijan
Nigeria
Bahamas
Namibia
Iceland
Iraq
United Arab Emirates
Jamaica
Honduras
Isle of Man
Bolivia
Luxembourg
Albania
Pakistan
Grenada
Romania
Jordan
Argentina
Bangladesh
Kazakhstan
Kenya
Cayman Islands
Cambodia
Oman
Cyprus
Latvia
Austria
Cameroon
Switzerland
Colombia
Guatemala
Marshall Islands
VC (Venture Capital) Funds in United States by industry
Transportation
Enterprise
FinTech
Health Care
Biotech
Consumer
Climate
Impact
Energy
Sustainability
Proptech
Community
Marketplace
Artificial intelligence
Gaming
SaaS
Venture Capital
Crowdfunding
Retail
LGBT
Financial Services
Film
Oil and Gas
Publishing
Cryptocurrency
Education
Payments
Wine And Spirits
Food and Beverage
Video Games
Restaurants
Medical
Franchise
Wellness
EdTech
Hardware
Email
Social Media
Digital Media
Manufacturing
Art
Celebrity
Theatre
Blockchain
Android
Social Impact
Mobile
Google
Legal
Software
Non Profit
Local
Enterprise Software
Finance
eSports
Sports
CleanTech
Hospitality
Automotive
InsurTech
Travel
Biotechnology
Cannabis
Platforms
Mobile Advertising
Real Estate
Infrastructure
Fashion
Social
Web3
Life Science
Photography
Sporting Goods
Big Data
Clean Energy
Construction
Mobile Apps
Medical Device
B2B
Social Network
Fitness
Renewable Energy
Music
Internet
Beauty
Agriculture (agtech)
Facebook
Media (entertainment)
Organic Food
Machine Learning
Recruiting